Menjugate (N. Meningitidis Group C (Strain C11) Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm19)

Menjugate is a conjugate vaccine indicated for prevention of meningococcal disease caused by Neisseria meningitidis serogroup C.

• Meningococcal meningitis (serogroup C): reduces incidence of meningitis caused by serogroup C strains.
• Meningococcemia (serogroup C): lowers risk of bloodstream infection from serogroup C bacteria.
• Invasive meningococcal disease (serogroup C): provides overall protection against severe invasive disease.

• Menjugate works by presenting the capsular polysaccharide of Neisseria meningitidis group C covalently linked to the non‑toxic diphtheria toxoid CRM197. The conjugate is taken up by antigen‑presenting cells, processed and displayed to T‑helper cells, which stimulate B‑cell production of high‑affinity anti‑polysaccharide antibodies, establishing long‑lasting protective immunity. This T‑cell dependent response overcomes the poor immunogenicity of polysaccharide antigens alone and generates immunological memory that can be boosted by subsequent doses.

Menjugate, like other conjugate vaccines, may be associated with local and systemic reactions following injection.

Common Side Effects

• Pain at injection site: mild to moderate discomfort lasting a few hours after the shot.
• Redness or swelling: transient erythema or edema at the injection area that resolves within a day.
• Fever: low‑grade temperature rise, typically 38 °C or less, occurring within 24‑48 hours.

Serious or Rare Side Effects

• Anaphylaxis: severe, potentially life‑threatening allergic reaction that requires immediate emergency treatment.
• Guillain‑Barré syndrome: rare autoimmune neuropathy that may develop weeks after vaccination.
• Seizures: infrequent febrile seizures, most commonly observed in young children following fever.

Before administering Menjugate, healthcare professionals should consider several precautionary measures to ensure safe use.

• Contraindication: known severe allergy to any vaccine component, including CRM197, should preclude use.
• Prior reaction: postpone vaccination if the patient experienced a serious adverse event after a previous dose of a meningococcal conjugate vaccine.
• Acute illness: defer vaccination in individuals with moderate or severe acute febrile illness until recovery.
• Immunocompromised status: assess risk‑benefit in patients with severe immunodeficiency, as immune response may be reduced.
• Age limitation: confirm that the patient’s age falls within the approved range for the vaccine.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Menjugate has limited potential for drug interactions, but certain concomitant therapies warrant attention.

Major Interactions (Avoid)

• Live bacterial vaccines: avoid simultaneous administration with other live bacterial vaccines due to possible immune interference.
• Immunoglobulin therapy: concurrent IVIG may diminish vaccine‑induced antibody response.

Moderate Interactions (Monitor Closely)

• Antipyretics: prophylactic use of acetaminophen or ibuprofen may reduce antibody titers; advise use only for symptom relief after vaccination.
• Immunosuppressants: corticosteroids or biologic agents may blunt immune response, consider timing of vaccination relative to therapy.
• Blood products: recent transfusion may affect immunogenicity; schedule vaccination appropriately.